1.Hidron AI, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infection Control and Hospital Epidemiology 2008; 29: 996–1011.
2.Deshpande LM, et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagnostic Microbiology and Infectious Diseases 2007; 58: 163–170.
3.NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. American Journal of Infection Control 2004; 32: 470–485.
4.Vergis EN, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Annals of Internal Medicine 2001; 135: 484–492.
5.Erlandson KM, et al. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clinical Infectious Diseases 2008; 46: 30–36.
6.DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. Journal of Infectious Diseases 2005; 191: 588–595.
7.Gearhart M, et al. Consequences of vancomycin-resistant Enterococcus in liver transplant recipients: a matched control study. Clinical Transplantation 2005; 19: 711–716.
8.Garbutt JM, et al. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clinical Infectious Diseases 2000; 30: 466–472.
9.Song JH, et al. Clinical implications of vancomycin-resistant Enterococcus faecium (VRE) with VanD phenotype and vanA genotype. Journal of Antimicrobial Chemotherapy 2008; 61: 838–844.
10.Song X, et al. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infection Control and Hospital Epidemiology 2003; 24: 251–256.
11.Papanicolaou GA, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clinical Infectious Diseases 1996; 23: 760–766.
12.DiazGranados CA, et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clinical Infectious Diseases 2005; 41: 327–333.
13.Warren RE. Daptomycin in endocarditis and bacteraemia: a British perspective. Journal of Antimicrobial Chemotherapy 2008; 62 (Suppl. 3): 25–33.
14.Schwartz BS, Ngo PD, Guglielmo BJ. Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding? Annals of Pharmacotherapy 2008; 42: 289–290.
15.Mohr JF, et al. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). International Journal of Antimicrobial Agents 2009; 33: 543–548.
16.Mave V, et al. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? Journal of Antimicrobial Chemotherapy 2009; 64: 175–180.
17.Camins BC, et al. A population-based investigation of invasive vancomycin-resistant Enterococcus infection in metropolitan Atlanta, Georgia, and predictors of mortality. Infection Control and Hospital Epidemiology 2007; 28: 983–991.
18.Bhavnani SM, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagnostic Microbiology and Infectious Diseases 2000; 36: 145–158.
19.Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. American Journal of Infection Control 2008; 36: 309–332.
20.Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987; 40: 373–383.
21.Boucher HW, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clinical Infectious Diseases 2009; 48: 1–12.
22.Reik R, et al. The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004. Diagnostic Microbiology and Infectious Diseases 2008; 62: 81–85.
23.Ghanem G, et al. Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients. Infection Control and Hospital Epidemiology 2007; 28: 1054–1059.
24.Poutsiaka DD, et al. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. Journal of Infection 2007; 54: 567–571.
25.Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006; 26: 347–332.
26.Raad II, et al. Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm. Antimicrobial Agents and Chemotherapy 2005; 49: 5046–5050.
27.Moellering RC, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. Journal of Antimicrobial Chemotherapy 1999; 44: 251–261.
28.Kvirikadze N, et al. Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scandinavian Journal of Infectious Diseases 2006; 38: 290–292.
29.Cunha BA, Mickail N, Eisenstein L. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart and Lung 2007; 36: 456–461.
30.Levine DP. Clinical experience with daptomycin: bacteraemia and endocarditis. Journal of Antimicrobial Chemotherapy 2008; 62 (Suppl. 3): 35–39.
31.Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clinical Infectious Diseases 2000; 30: 146–151.
32.Fowler VG Jr., et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clinical Infectious Diseases 1998; 27: 478–486.
33.Patel M, et al. Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines. Diagnostic Microbiology and Infectious Diseases 2005; 52: 29–34.